A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer

Duration of Response

Among tumor responders, the duration of tumor response is measured from the date of response (complete response \[CR\] or partial response \[PR\]) until the first date of documented progression or death from any cause. Duration of tumor response will be censored at the date of the last follow-up visit for tumor responders who are still alive and who have not progressed.

Time frame: date of response (CR or PR) until the first date of documented progression or death from any cause (up to 3.5 years)

Number of Patients Who Experienced Alopecia

Time frame: Baseline to 3.5 years

Time to Disease Progression (TTP)

If a patient is lost to follow-up, the patient will be censored as of the last date of contact. Patients who start a new treatment before they progress will be censored as of the date of start of the new treatment. If a patient died due to reason other than study disease, and patient has not progressed or received any new treatment, TTP is censored at the date of death.

Time frame: randomization date to the earliest date of the first documented disease progression date or the date of death if the patient dies due to study disease (up to 3.5 years)

Percentage of Patients With Overall Survival at 1 Year and 2 Years

Kaplan-Meier estimates of overall survival (percentage of patients surviving) at 1 year and 2 years.